Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 40 mg injection once weekly
TASP_SC_40MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.63 (0.01 to 43.27) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.69 (0.23 to 11.90) | 0.45 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.68 (0.10 to 23.32) | 0.36 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.40 (1.76 to 10.83) | 0.31 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.45 (1.48 to 27.33) | 0.26 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.03 (0.23 to 3.85) | 0.66 |